Are there significant gains ahead for one (or both) of these innovative biotechs?

Researchers at Cornell University have developed a safer and more precise way to study how genes function in living tissues by refining a recently developed CRISPR-based genetic technique in fruit ...

Researchers at Cornell University have developed a safer and more precise way to study how genes function in living tissues by refining a recently developed CRISPR-based genetic technique in fruit ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday.

CRISPR-based genome editing has transformed biological research. Since the advent of the technology in 2012, Addgene has ...

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

Q1 results and earnings estimate revisions put CRISPR Therapeutics (CRSP) in focus CRISPR Therapeutics (CRSP) has moved back onto investors’ radar after reporting a Q1 2026 net loss of US$122.9 ...

2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...

The biotech's candidate may treat a great number of illnesses that have one thing in common.

Learn how CRISPR ETFs provide access to the gene-editing revolution, offering investors a diversified approach without picking individual biotech stocks.

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.